122
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Clinical Characteristics and Risk Factors for Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae (CrKP): A Cohort Study from Developing Country

, , , ORCID Icon, , , & ORCID Icon show all
Pages 5555-5562 | Published online: 20 Dec 2021

References

  • Bengoechea José A, Joana SP. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2018;43(2):123–144.
  • Kazmierczak KM, De Jonge B, Stone GG, et al. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. J Antimicrob Chemother. 2020;75(5):1165–1173.32040168
  • Pagano L, Caira M, Trecarichi EM, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014;20(7):1235–1236.24960464
  • Huang M, He P, Munir S, et al. Ecology and etiology of bacterial top rot in maize caused by Klebsiella pneumoniae KpC4. Microb Pathog. 2020;139:103906.31786257
  • Karlsson M, Stanton RA, Ansari U, et al. Identification of a carbapenemase-producing hypervirulent Klebsiella pneumoniae isolate in the United States. Antimicrob Agents Chemother. 2019;63(7):e00519.31061159
  • Arena F, Henrici De Angelis L, D’Andrea MM, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae with hypermucoviscous phenotype: a case report and literature review. Virulence. 2017;8(8):1900–1908.28276993
  • Zhong XS, Li YZ, Ge J, et al. Comparisons of microbiological characteristics and antibiotic resistance of Klebsiella pneumoniae isolates from urban rodents, shrews, and healthy people. BMC Microbiol. 2020;20(1):12.31937244
  • Niu G, Li W. Next-generation drug discovery to combat antimicrobial resistance. Trends Biochem Sci. 2019;44(11):961–972.31256981
  • Soares M, Dongelmans DA. Why should we not use APACHE II for performance measurement and bench marking? Rev Bras Ter Intensiva. 2017;29:268–270.28876406
  • Lee H, Lim CW, Hong HP, et al. Efficacy of the APACHE II score at ICU discharge in predicting post-ICU mortality and ICU readmission in critically ill surgical patients. Anaesth Intensive Care. 2015;43(2):175–186.25735682
  • Czajka S, Ziębińska K, Marczenko K, Posmyk B, Szczepańska AJ, Krzych KJ. Validation of APACHE II, APACHE III and SAPS II scores in in-hospital and one year mortality prediction in a mixed intensive care unit in Poland: a cohort study. BMC Anesthesiol. 2020;20(1):296.33267777
  • Breslow MJ, Badawi O. Severity scoring in the critically ill: part 1–interpretation and accuracy of outcome prediction scoring systems. Chest. 2012;141(1):245–252.22215834
  • Serpa Neto A, Assunção MS, Pardini A, Silva E. Feasibility of transitioning from APACHE II to SAPS III as prognostic model in a Brazilian general intensive care unit. A retrospective study. Sao Paulo Med J. 2014;133(3):199–205.25337664
  • Williams JM, Greenslade JH, Chu K, Eliézer S. Severity scores in emergency department patients with presumed infection: a prospective validation study. Crit Care Med. 2016;44(3):539–547.26901543
  • Hashmi M, Asghar A, Shamim F, Khan FH. Validation of acute physiologic and chronic health evaluation II scoring system software developed at the Aga Khan University, Pakistan. Saudi J Anaesth. 2016;10(1):45–49.26955310
  • Thanapaisal C, Saksaen P. A comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II score and the Trauma-Injury Severity Score (TRISS) for outcome assessment in Srinagarind Intensive Care Unit trauma patients. J Med Assoc Thai. 2012;95(Suppl 11):S25–33.23961616
  • Moreno RP, Júnior N, Paulo A. Is APACHE II a useful tool for clinical research. Rev Bras Ter Intensiva. 2017;29(3):264–267.29044301
  • Sun YS, Yu JL. Clinical value of blood lactate in predicting the mortality of neonatal sepsis. Chin J Contemp Ped. 2019;21(7):629–634.
  • Verhaeghe M, Saïd H-I. Blood lactate and lactate kinetics as treatment and mortality markers for tissue hypoperfusion. Acta Clin Belg. 2020;75(1):1–8.30591001
  • Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Intensive Care Med. 2018;44(6):925–928.29675566
  • Vincent JL, Quintairos E, Silva A, Couto L Jr, Taccone FS. The value of blood lactate kinetics in critically ill patients: a systematic review. Crit Care. 2016;20(1):257.27520452
  • Jones Alan E, Shapiro Nathan I, Stephen T, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303(8):739–746.20179283
  • Ryoo SM, Lee J, Lee YS, et al. Lactate level versus lactate clearance for predicting mortality in patients with septic shock defined by Sepsis-3. Crit Care Med. 2018;46(6):e489–e495.29432347
  • Amladi AU, Abirami B, Devi SM, et al. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian J Med Res. 2019;149(2):185–191.31219082
  • Abe R, Hagiya H, Akeda Y, Sudarsanam TD, Kandasamy S, Kekre N. Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae. BMC Res Notes. 2019;12(1):740.31706328
  • Abbas HA, Kadry AA, Shaker GH, Goda RM. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates. Microb Pathog. 2019;132:266–274.31096002
  • Zhang J, Yu L, Fu Y, et al. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro. Ann Palliat Med. 2019;8(5):622–631.31735038
  • Zhou Y, Wang J, Guo Y, et al. Discovery of a potential MCR-1 inhibitor that reverses polymyxin activity against clinical mcr-1-positive Enterobacteriaceae. J Infect. 2019;78(5):364–372.30851289
  • Ulloa ER, Dillon N, Tsunemoto H, et al. Avibactam sensitizes carbapenem-resistant NDM-1–producing Klebsiella pneumoniae to innate immune clearance. J Infect Dis. 2019;220(3):484–493.30923801
  • Mikhail S, Singh NB, Mikhail RK, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(8):00779–00819.
  • Liang Q, Huang M, Xu Z. Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Braz J Infect Dis. 2019;23(1):60–65.30796888